BRISTOL MYERS SQUIBB
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00162201
- Locations
- ๐ฌ๐ง
Local Institution, Leeds, Essex, United Kingdom
A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00162448
- Locations
- ๐บ๐ธ
Local Institution, Columbus, Ohio, United States
ATV/Ritonavir Nevirapine Interaction (USPAC)
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00162149
- Locations
- ๐ฌ๐ง
Local Institution, London, Greater London, United Kingdom
PPAR - Combination With Metformin
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 534
- Registration Number
- NCT00162240
- Locations
- ๐ฌ๐ง
Local Institution, Swan Lake, United Kingdom
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 248
- Registration Number
- NCT00162123
- Locations
- ๐บ๐ธ
The Angeles Clinic & Research Inst., Los Angeles, California, United States
๐บ๐ธUniversity Of Chicago, Chicago, Illinois, United States
๐บ๐ธIndiana Oncology Hematology Consultants, Indianapolis, Indiana, United States
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Atazanavir+ritonavirDrug: Lopinavir+ritonavir
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00135395
- Locations
- ๐ต๐ท
Local Institution, Santruce, Puerto Rico
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: Ipilimumab+ Placebo
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT00135408
- Locations
- ๐ฌ๐ง
Local Institution, Hull, United Kingdom
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
Phase 1
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 271
- Registration Number
- NCT00135421
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
๐บ๐ธAlbuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States
๐บ๐ธUniversity Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
Phase 3
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 254
- Registration Number
- NCT00135382
- Locations
- ๐ต๐ท
Local Institution, Rio Piedras, Puerto Rico
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
Phase 4
Completed
- Conditions
- HIV-Associated Lipodystrophy Syndrome
- Interventions
- Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 219
- Registration Number
- NCT00135356
- Locations
- ๐ฌ๐ง
Local Institution, London, Greater London, United Kingdom
ยฉ Copyright 2025. All Rights Reserved by MedPath